Design and Synthesis of trans-3-(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido) cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D3 Receptor Antagonist

Journal of Medicinal Chemistry

Volumn 46, Issue 23, 2003, Pages 4952-4964

  Macdonald, Gregor J ^a   Branch, Clive L ^a   Hadley, Michael S ^a   Johnson, Christopher N ^a   Nash, David J ^a   Smith, Alexander B ^a   Stemp, Geoffrey ^a   Thewlis, Kevin M ^a   Vong, Antonio K K ^a   Austin, Nigel E ^a   Jeffrey, Phillip ^a   Winborn, Kim Y ^a   Boyfield, Izzy ^a   Hagan, Jim J ^a   Middlemiss, Derek N ^a   Reavill, Charlie ^a   Riley, Graham J ^a   Watson, Jeannette M ^a   Wood, Martyn ^a   Parker, Steve G ^a   Ashby Jr , Charles R ^b   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 1H ISOINDOLINE; 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 3 [2 [4 [[3 [3 (5 METHYL 1,2,4 OXADIAZOLYL)]PHENYL]CARBOXAMIDO]CYCLOHEXYL]ETHYL] 7 METHYLSULFONYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPINE; 7 SULFONYLBENZAZEPINE; 7 SULFONYLOXYBENZAZEPINE; CYTOCHROME P450; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; SB 414796; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MALE; NONHUMAN; RAT; RECEPTOR AFFINITY; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0242302620     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030817d     Document Type: Article

References (34)

1. 3 receptor: basic and clinical aspects. Clin. Neuropharmacol. 1993, 16, 295-314.
2. Moller, H. J.; Boyer, P.; Fleurot, O.; Rein, W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997, 4, 132, 396-401.
3. 3) as a target for neuroleptic drugs. Nature 1990, 347, 146.
4. 3 dopamine receptor in cellular and organismal function. Psychopharmacology 1998, 135, 1-16.
5. 2 receptors to neuronal circuits in human brain: insights into schizophrenia. Neuropsychopharmacology 1997, 16, 375.
6. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 2000, 43, 1878-1885.
7. Reavill, C.; Taylor, S. G.; Wood, M. D.; Ashmeade, T.; Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Cilia, J.; Coldwell, M. C.; Hadley, M. S.; Hunter, J.; Jeffrey, P.; Jewitt, F.; Johnson, C. N.; Jones, D. N. C.; Medhurst, A. D.; Middlemiss, D. N.; Nash, D. J.; Riley, G. J.; Routledge, C.; Stemp, G.; Thewlis, K. M.; Trail, B.; Vong, A. K. K. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165.
8. White, F. J.; Wang, R. Y. Differential effects of classical atypical antipsychotic drugs on A9/A10 dopamine neurons. Science 1983, 221, 1054-1057.
9. Ashby, C. R.; Minabe, Y.; Stemp, G.; Hagan, J. J.; Middlemiss, D. N. Acute and chronic administration of the selective D3 receptor antagonist SB-277011-A alters activity of the midbrain dopamine neurons in rats: an in vivo electro-physiological study. J. Pharmacol. Exp. Ther. 2000, 294, 1166-1174.
10. Gardner, E. L. Brain Reward Mechanisms. Substance Abuse: A Comprehensive Textbook, 3rd ed.; Williams & Wilkins: Baltimore, pp 51-85.
11. Wise, R. A.; Rompre P-P. Brain dopamine and reward. Annu. Rev. Psychol. 1989, 40, 191-225.
12. 3 agonist. Nature 1999, 400, 371-375.
13. 3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22, 9595-9603.
14. 3 dopamine receptor antagonist SB-277011-A. Neuropharmacology, in press.
15. 3 receptor antagonist SB-277011 in rat, dog and monkey: in vitro/in vivo correlation and the role of aldehyde oxidase. Xenobiotica 2001, 31 (8/9), 677-686.
16. 3 receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 2059-2064.
17. 3 receptor. Bioorg. Med. Chem. Lett. 1995, 5, 219-222.
18. Belliotti, T. R.; Kesten, S. R.; Rubin, J. R.; Wustrow, D. J.; Georgic, L. M.; Zoski, K. T.; Akunne, H. C.; Wise, L. D. Novel cyclohexyl amides as potent and selective D3 dopamine receptor ligands. Bioorg. Med. Chem. Lett. 1997, 7, 2403-2408.
19. Yuan, J.; Chen, X.; Brodbeck, R.; Primus, R.; Braun, J.; Wasley, J. W. F.; Thurkauf, A. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg. Med. Chem. Lett. 1998, 8, 2715-2718.
20. 3 receptor. Bioorg. Med. Chem. Lett. 1997, 7, 485-488.
21. 3 receptor. Bioorg. Med. Chem. Lett. 1997, 7, 1995-1998.
22. Starck, D.; Treiber, H. J.; Unger, L.; Neumann-Schultz, B.; Blumbach, K. ; Schbel, D. Patent WO 0042036, 2000.
23. 3 receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans. J. Med. Chem. 2001, 44, 4716-4732.
24. 3 receptor. Bioorg. Med. Chem. Lett. 2000, 10, 2553-2555.
25. Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Hadley, M. S.; Jeffrey, P.; Johnson, C. N.; Macdonald, G. J.; Nash, D. J.; Riley, G. J.; Smith, A. B.; Stemp, G.; Thewlis, K. M.; Vong, A. K. K.; Wood, M. Design and synthesis of novel 2,3-dihydro-1H-isoindoles with high affinity and selectivity for the dopamine D3 receptor. Bioorg. Med. Chem. Lett. 2001, 11, 685-688.
26. Hadley, M. S.; Johnson, C. N.; Macdonald, G. J.; Stemp, G.; Vong, A. K. K. Patent WO 00/21951, 2000.
27. 4.4 receptors expressed in Chinese hamster ovary cells. Br. J. Pharmacol. 1999, 127, 1135-1144.
28. Dewey, S. L.; Morgan A. E.; Ashby, C. R.; Horan, B.; Kushner, S. A.; Logan, J.; Volkow, N. D.; Fowler, J. S.; Gardner, E. L.; Brodie, J. D. A novel strategy for the treatment of cocaine addiction. Synapse 1998, 30, 119-129.
29. (a) CYP2D6 (MMMC): Clark, S. E. Patent WO 99/58710.
30. (b) CYP2C9 (FCA): Bamal, R. B. Patent WO 00/22159.
31. (c) CYP3A4 (PPR): Bloomer, J. C.; Elliot, R. L.; Leach, C. A. Patent WO 00/ 44933.
32. (d) CYP3A4 (DEF): Bamal, R.; Bloomer, J. C. Patent WO 01/44495.
33. (e) CYP2C19 (BMC): Bloomer, J. C.; Leach, C. A. Patent WO 02/12542.
34. 14C-methyl] caffeine. Xenobiotica 1985, 25, 9, 917-927.